FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to a method for diagnosing non-alcoholic hepatic steatosis using laboratory tests, in which the patient's body weight and height are measured to calculate the body mass index, the level of gamma-glutamyl transpeptidase, vasculoendothelial growth factor and interleukin-6 is determined in the blood serum and the index is calculated steatosis, and if the steatosis index is equal to or more than 0.5, the presence of non-alcoholic hepatic steatosis is diagnosed, with the steatosis index less than 0.5 - the absence of non-alcoholic hepatic steatosis.
EFFECT: invention provides a reduction in trauma, availability and ease of execution with high sensitivity and specificity.
1 cl, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETERMINING THE RISK OF SEVERE LIVER STEATOSIS | 2023 |
|
RU2806496C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSING NON-ALCOHOLIC FATTY LIVER DISEASE BASED ON THE IDENTIFICATION OF MIRNAS AND MIP-1β IN BLOOD PLASMA | 2022 |
|
RU2798163C1 |
| METHOD FOR DIAGNOSING NON-ALCOHOLIC HEPATIC STEATOSIS IN MENOPAUSAL WOMEN | 2022 |
|
RU2785905C1 |
| METHOD FOR DIAGNOSING HEPATIC STEATOSIS IN POSTMENOPAUSAL OVERWEIGHT OR OBESE WOMEN | 2024 |
|
RU2830801C1 |
| METHOD OF TREATING NONALCOHOLIC FATTY LIVER DISEASE WITH USE OF PENTOXIFYLLINE AMPLI-PULSE PHORESIS | 2014 |
|
RU2548775C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
| METHOD OF DIAGNOSING METABOLIC SYNDROME | 2010 |
|
RU2444298C1 |
| METHOD OF SCREENING HEPATIC DISORDERS, AND SYSTEM FOR IMPLEMENTING METHOD | 2013 |
|
RU2523661C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF ALCOHOLIC LIVER DISEASE IN MALES | 2022 |
|
RU2814367C1 |
